The DOI matches its Crossref record.
Cost-effectiveness of cholesterol lowering: Results from the Scandinavian Simvastatin Survival Study (4S)
Abstract
An analysis of the cost-effectiveness of simvastatin was conducted, based on the Scandinavian Simvastatin Survival Study (4S). The total cost of hospitalization in the placebo group was 52.8 million Swedish kronor (SEK) (5.15 million pounds), compared with SEK 36.0 million (3.51 million pounds) in the simvastatin group. This amounts to a 32% reduction, or a saving of SEK 16.8 million (1.6 million pounds) or SEK 7560 (738 pounds) per patient. The net cost per patient for the duration of the study (5.4 years) was SEK 13,540 (1324 pounds). Simvastatin treatment saved an estimated 0.377 undiscounted life years (0.240 life years discounted at 5% per annum). The cost of simvastatin therapy per discounted life-year saved was therefore SEK 56,400 (5502 pounds). Sensitivity analysis, examining the effect of different life expectancies, costs of initiation and monitoring of simvastatin therapy, and discount rates, showed the results to be stable. Conclusion. The cost per life-year saved of simvastatin in the treatment of post-myocardial infarction and angina patients, as determined from 4S data, is well within the range normally considered cost-effective.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Wood, D., De Backer, G., Faergeman, O., Graham, I., Mancia, G., & Pyörälä, K. (1998) · Atherosclerosis · doi:10.1016/s0021-9150(98)90209-x · Cited by 1,255
A systematic review and economic evaluation of statins for the prevention of coronary events
Ward, S., Lloyd Jones, M., Pandor, A., Holmes, M., Ara, R., Ryan, A., Yeo, W., & Payne, N. (2007) · Health Technology Assessment · doi:10.3310/hta11140 · Cited by 556
Generalisability in economic evaluation studies in healthcare: a review and case studies
Sculpher, M., Pang, F., Manca, A., Drummond, M., Golder, S., Urdahl, H., Davies, L., & Eastwood, A. (2004) · Health Technology Assessment · doi:10.3310/hta8490 · Cited by 441
Handling uncertainty when performing economic evaluation of healthcare interventions.
Briggs, & Gray (1999) · Health Technology Assessment · doi:10.3310/hta3020 · Cited by 387
Johannesson, M., Jönsson, B., Kjekshus, J., Olsson, A. G., Pedersen, T. R., & Wedel, H. (1997) · New England Journal of Medicine · doi:10.1056/nejm199701303360503 · Cited by 387
Self-citation
Metadata
- Authors
- Jonsson, B., Johannesson, M., Kjekshus, J., Olsson, A. G., Pedersen, T. R., Wedel, H., & Scandlnavlan Simvastatin Survival Study Group
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 1996-07-01
- Volume
- 17
- Issue
- 7
- Pages
- 1001-1007
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W2183761985
- Cited by
- 176
- References
- 0
- FWCI
- 24.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cost-effectiveness of cholesterol lowering: Results from the Scandinavian Simvastatin Survival Study (4S). https://app.cochat.ai/papers/10.1093/oxfordjournals.eurheartj.a014994
- The paper
- Jonsson, B., Johannesson, M., Kjekshus, J., Olsson, A. G., Pedersen, T. R., Wedel, H., & Scandlnavlan Simvastatin Survival Study Group. (1996). Cost-effectiveness of cholesterol lowering: Results from the Scandinavian Simvastatin Survival Study (4S). European Heart Journal. https://doi.org/10.1093/oxfordjournals.eurheartj.a014994
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.